Dr. Samli specializes in commercializing applied-technologies. His engagements include securing and deploying capital, and demonstrating significant stakeholder value generation across industries (including bio, quantum, and blockchain), non-profit organizations, and academia. As a thought-leader, internationalist, and executive he leads and advises teams on strategy, technology commercialization, organizational development, and building ecosystems.

Dr. Samli served as SVP Global Services for Learning Machine (acquired by Hyland Software). He served as COO at 1QBit, a quantum computing software company developing hardware-agnostic platforms and services for applications in machine learning, optimization, and simulation. He also served as CEO at Lectenz Bio, a biotech company developing novel biomarker detection technologies and products.

In service to communities, he is an Expert for Horizon Europe (previously Horizon 2020) for the European Commission, an Investigator for Creative Destruction Lab (Vancouver), an Ignite Review Panelist for Innovate BC, and a member of Singularity University’s Faculty. He serves as a Director on the Boards of Genome BC, Lectenz Bio, and Women@TheFrontier. He holds a Ph.D. in biochemistry and molecular biology (computational chemistry) from the University of Georgia, a M.S. in chemistry from Arizona State University, and a B.S. in biochemistry from the University of Texas at Austin. He attended Singularity University’s Global Solutions Program specializing in technology entrepreneurship, commercialization, and sustainable development goals and has co-founded multiple start-ups.